Update on Burkitt Lymphoma

Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges...

Full description

Saved in:
Bibliographic Details
Published inHematology/oncology clinics of North America Vol. 30; no. 6; p. 1333
Main Authors Dunleavy, Kieron, Little, Richard F, Wilson, Wyndham H
Format Journal Article
LanguageEnglish
Published United States 01.12.2016
Subjects
Burkitt Lymphoma - genetics
Burkitt Lymphoma - metabolism
Burkitt Lymphoma - therapy
Humans
Mutation
Proto-Oncogene Proteins c-myc - genetics
Proto-Oncogene Proteins c-myc - metabolism
CCND3
Sporadic
MYC
Burkitt lymphoma
ID3
TCF3
Risk-adapted
Endemic
Online AccessGet more information

Cover

More Information
Summary:Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges of most standard approaches typically used is severe treatment-related toxicity that often leads to discontinuation of therapy. To that point, there has been recent success developing intermediate intensity approaches that are well tolerated in all patient groups and maintain high cure rates in a multicenter setting.
ISSN:1558-1977
DOI:10.1016/j.hoc.2016.07.009